Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

MLA

Richez, Valentine, et al. “Carfilzomib Weekly 20/56 Mg/m 2 , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma.” American Journal of Hematology, vol. 94, no. 1, Jan. 2019, pp. E17–20. EBSCOhost, https://doi.org/10.1002/ajh.25327.

APA

Richez, V., Gruchet, C., Guidez, S., Fouquet, G., Azais, I., Durand, G., Javaugue, V., Brigaud, A., Plasse, F., Diolez, J., Machet, A., Moya, N., Gardeney, H., Franques, P., Bobin, A., Levy, A., Sabirou, F., Bonnin, A., Dieval, C., … Leleu, X. (2019). Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. American Journal of Hematology, 94(1), E17–E20. https://doi.org/10.1002/ajh.25327

Chicago

Richez, Valentine, Cecile Gruchet, Stephanie Guidez, Guillemette Fouquet, Isabelle Azais, Geraldine Durand, Vincent Javaugue, et al. 2019. “Carfilzomib Weekly 20/56 Mg/m 2 , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma.” American Journal of Hematology 94 (1): E17–20. doi:10.1002/ajh.25327.